Familial Partial Lipodystrophy Clinical Trial
Official title:
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02654977 -
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
|
Phase 2 | |
Completed |
NCT03508687 -
Study of Gemcabene in Adults With FPLD
|
Phase 1/Phase 2 | |
Completed |
NCT02430077 -
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
|
Phase 2 | |
Terminated |
NCT05088460 -
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
|
Phase 2 | |
Terminated |
NCT02527343 -
The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy
|
Phase 2/Phase 3 | |
Available |
NCT02404896 -
Expanded Access Metreleptin Study
|